Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors
Open Access
- 1 September 1998
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 9 (9) , 1003-1008
- https://doi.org/10.1023/a:1008487932384
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1994
- A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neckAnnals of Oncology, 1994
- Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)Annals of Oncology, 1994
- Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.Journal of Clinical Oncology, 1992
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabineCancer Chemotherapy and Pharmacology, 1991
- Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosidesThe Journal of Organic Chemistry, 1988